The historical rank and industry rank for Day One Biopharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:
DAWN's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 32.23 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -79.90% per year.
During the past 5 years, Day One Biopharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was -79.90% per year. The lowest was -150.40% per year. And the median was -115.15% per year.
Day One Biopharmaceuticals Price-to-Free-Cash-Flow Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Day One Biopharmaceuticals Price-to-Free-Cash-Flow Chart
Competitive Comparison of Day One Biopharmaceuticals's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Day One Biopharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Day One Biopharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Day One Biopharmaceuticals's Price-to-Free-Cash-Flow falls into.
Day One Biopharmaceuticals Price-to-Free-Cash-Flow Calculation
Day One Biopharmaceuticals's Share Price of today is $16.62. Day One Biopharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Day One Biopharmaceuticals (NAS:DAWN) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Day One Biopharmaceuticals Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Day One Biopharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Day One Biopharmaceuticals (Day One Biopharmaceuticals) Business Description
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DAWN has been successfully added to your 